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Recent European Society of Cardiology and American Heart Association/American College of Cardiology Guidelines did not
recommend biomarker-guided therapy in the management of heart failure (HF) patients. Combination of echo- and B-type
natriuretic peptide (BNP) may be an alternative approach in guiding ambulatory HF management. Our aim was to determine
whether a therapy guided by echomarkers of left ventricular ﬁlling pressure (LVFP), lung ultrasound (LUS) assessment of B-lines,
and BNP improves outcomes of HF patients. Consecutive outpatients with LV ejection fraction (EF)≤ 50% have been pro-
spectively enrolled. In Group I (n � 224), follow-up was guided by echo and BNP with the goal of achieving E-wave deceleration
time (EDT)≥ 150ms, tissue Doppler index E/e′ < 13, B-line numbers< 15, and BNP≤ 125 pg/ml or decrease >30%; in Group II
(n � 293), follow-up was clinically guided, while the remaining 277 patients (Group III) did not receive any dedicated follow-up.
At 60 months, survival was 88% in Group I compared to 75% in Group II and 54% in Group III (χ2 53.5; p< 0.0001). Survival
curves exhibited statistically signiﬁcant diﬀerences usingMantel–Cox analysis./e number needed to treat to spare one death was
7.9 (Group I versus Group II) and 3.8 (Group I versus Group III). At multivariate Cox regression analyses, major predictors of all-
cause mortality were follow-up E/e′ (HR: 1.05; p � 0.0038) and BNP >125 pg/ml or decrease ≤30% (HR: 4.90; p � 0.0054), while
BNP> 125 pg/ml or decrease ≤30% and B-line numbers ≥15 were associated with the combined end point of death and HF
hospitalization. Evidence-based HF treatment guided by serum biomarkers and ultrasound with the goal of reducing elevated
BNP and LVFP, and resolving pulmonary congestion was associated with better clinical outcomes and can be valuable in guiding
ambulatory HF management.
1. Introduction
Historically, the response to unloading therapy of elevated
LV ﬁlling pressure (LVFP) has been identiﬁed as an im-
portant mode to risk stratify patients with heart failure (HF)
who underwent right heart catheterization [1]. Recent ad-
vances support the value natriuretic peptide (NP) circulating
level assessment [2] and pulmonary artery pressure moni-
toring [3, 4] as tools for scrutinizing patients with impending
clinically overt HF. It is well known that similar hemody-
namic information to that provided by the invasive standard
can be obtained noninvasively by Doppler echocardiogra-
phy; particularly, an E-wave deceleration time (EDT)< 150ms and a ratio of E/averaged myocardial early velocity
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(averaged E/e′)≥ 13 have been found to reliably reﬂect in-
creased LVFP and worse prognosis [5–7], whereas reversal
of these alterations has been associated with more favorable
outcomes [8, 9]. Combining lung ultrasound (LUS) as-
sessment of B-lines with EDT and E/e′ may increase the
diagnostic accuracy in estimating LVFP and in identifying
pulmonary congestion [10]. /erefore, the combination of
Doppler echocardiographic markers of LVFP, LUS, and NPs
may be potentially valuable in guiding ambulatory HF
management, since they can be useful in distinguishing
stable patients from those at high risk of decompensation,
optimizing treatment, reducing hospitalization, and con-
sequently improving prognosis [11, 12]. To investigate this
concept, we compared the outcome of ambulatory patients
with chronic HF and reduced or mildly reduced LV ejection
fraction (EF) divided according to follow-up strategies: echo
Doppler signs of elevated LVFP, LUS, and B-type natriuretic
peptide (BNP)-directed follow-up (Group I); symptom-
guided follow-up (Group II); and no organized follow-up
for cardiovascular care (Group III).
2. Materials and Methods
/is observational study included consecutive ambulatory
patients with chronic HF and reduced or mildly reduced
LVEF. All patients underwent baseline evaluation by an
experienced cardiologist, including blood tests and 12-lead
ECG. Patients’ functional status was determined according
to the classiﬁcation of the New York Heart Association
(NYHA). At baseline, complete M-mode, two-dimensional,
and Doppler echocardiogram was carried out in all study
patients according to the recommendations of the European
Association of Echocardiography/American Association of
Echocardiography [13].
/e study population comprised of patients enrolled
between 2001 and 2016:
(1) Group I: 224 patients from the dedicated outpatient
ambulatory of the Cardiovascular Division of the
Cardiovascular and /oracic Department of the
University Hospital of Pisa, whose management was
directed according to the presence of echo Doppler
signs of elevated LVFP, LUS, and BNP levels. At each
visit, patients were clinically assessed (history,
clinical examination, NYHA class, and weight) and
were classiﬁed according to the Framingham criteria
[14]. Blood was drawn for BNP assay and measure of
renal function. An echocardiogram was carried out
for assessing LVFP, as an adjunct to the physical
examination in case of inconclusive signs and
symptoms and BNP >125 pg/ml [15]. /e following
Doppler echocardiographic ﬁndings were consid-
ered as surrogate markers of increased LVFP:
E/e′ ≥ 13 and EDT < 150ms. /e echographic ex-
amination of the lungs for B-lines assessment was
eventually performed, and patients were classiﬁed
according to B-line numbers ≥15 and <15 [16].
/erapeutic interventions were made according to
a titration protocol (Figure 1). Our aim was to
optimize treatment with neurohormonal drugs in
compensated HF patients and to lower elevated BNP
and LVFP and resolve pulmonary congestion in
decompensated HF patients. /e frequencies of
follow-up visits were decided on the basis of physical,
biochemical, and echographic ﬁndings.
(2) Group II: 293 consecutive patients from the dedi-
cated outpatient ambulatory of the HF Unit of the
Cardiovascular and /oracic Department of the
University Hospital of Pisa, whose management was
clinically guided according to a standardized pro-
tocol that included medical history, clinical exami-
nation, blood tests, and 12-lead ECG. /ese patients
underwent an echocardiographic examination at
baseline and again if clinical changes occurred. In
this group, NPs were not systematically evaluated
during follow-up. /e frequencies of follow-up visits
were based on clinical judgment.
(3) Group III: 277 consecutive ambulatory patients from
the Cardiovascular Division of Santa Chiara Hospital
of Pisa. Patients of this group did not receive
a speciﬁc follow-up for cardiovascular care and were
mostly followed by their family physicians who were
consulted in case of relapses.
/e study was approved by the local institutional review
boards. All patients gave written informed consent. /e
study was conducted in accordance with institutional pol-
icies, national legal requirements, and the revised Helsinki
Declaration.
Information on patients’ outcomes was obtained
through clinical visits, personal communication with general
Decompensated
Framingham criteria ≥2
Compensated
Framingham criteria <2
Clinical evaluation
NYHA class, weight,
physical examination
BNP < 125 pg/ml or
 decreased >30%
BNP ≥ 125 pg/ml or 
decreased ≤30% 
Echocardiography
(EDT and E/e′) + LUS
No congestion Congestion
Uptitration of ACEI (or ARB)
and BB to target doses
May decrease diuretics
May consider ARNI and
ivabradine
Increase diuretics
May add or increase MRI
May reduce BB
Figure 1: Predeﬁned titration protocol. ACEI: angiotensin-con-
verting enzyme inhibitors; ARB: angiotensin receptor blockers;
ARNI: angiotensin receptor neprilysin inhibitors; BB: beta-
blockers; BNP: B-type natriuretic peptide; EDT: E-wave de-
celeration time; E/e′: ratio of E/averaged myocardial early velocity;
MRI: mineralocorticoid receptors inhibitors; LUS: lung ultrasound.
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physicians, and telephone interviews with patients and
relatives, by trained personnel. /e primary study end
point was all-cause mortality, and the secondary end point
was the combination of death and hospitalization for
worsening HF.
Data are summarized using frequencies (percentages)
for categorical variables and mean± standard deviation for
continuous variables or median interquartile (IRQ) ranges,
when appropriate. Diﬀerences between the three groups
were tested by analysis of variance (ANOVA) using
Bonferroni test. Demographic, clinical, and echo variables
were evaluated for the end points in a univariable Cox
proportional hazard model (95% conﬁdence intervals).
Variables showing signiﬁcant association with outcome
(p< 0.1) were included in the multivariable Cox model to
determine the ones independently related to prognosis. /e
cumulative survival probability was explored using the
Kaplan–Meier method, followed by the log-rank test.
Diﬀerences of survival curves were tested with Mantel–Cox
statistic log-rank analysis. A p value <0.05 was considered
statistically signiﬁcant. All analyses were performed using
the IBM SPSS Software Package version 17.0.1.
3. Results
Table 1 outlines the baseline demographic, clinical, and
echocardiographic characteristics of the three groups. In
Group I, baseline BNP was 290 pg/ml (IRQ: 163–571) and
follow-up BNP at 6± 4months was 155 pg/ml (IRQ: 58–333)
(Mann–Whitney p< 0.0001).
Figure 2 shows percentages of patients of Group I that
exhibited echo Doppler markers of raised LVFP and LUS
B-line numbers ≥15 at baseline and after 6-month follow-
up. Patients who had low BNP levels (≤125 pg/ml) at 6-
month follow-up were 23%, 45% of patients had a 6-month
decrease >30% from elevated BNP baseline levels, and 34%
had elevated BNP levels (>125 pg/ml) at follow-up without
any 6-month decrease >30% from their baseline value.
/e median follow-up duration was 36 months (IRQ:
17–58) and was comparable in the three groups. Forty-nine
events (23 deaths and 26 hospitalizations related to HF)
occurred in Group I, 106 in Group II (66 deaths and 40
hospitalizations due to HF), and 152 in Group III (100 deaths
and 52 hospitalizations due to HF), respectively. /e mean
number of follow-up visits/year was 2.5± 1.7 in Group I
patients and 2.8± 1.7 in Group II patients.
At 60-month follow-up, survival free from all-cause
mortality was 88% in Group I patients, 75% in Group II
patients, and 54% in Group III patients (X2 53.5;
p< 0.0001). Mantel–Cox analysis showed signiﬁcant dif-
ferences between Group I and Group II patients (X2 8.8; p �
0.003), between Group I and Group III patients (X2 46.2;
p< 0.0001), and between Group II and Group III patients
(X2 21.5; p< 0.0001) (Figure 3). /e strategy based on echo
and BNP improved the probability of survival by 12.5%
versus the symptom-guided follow-up and by 40.7% versus
the nonspeciﬁc follow-up care. /e number needed to treat
to spare one death was 8 (Group I versus Group II) and 4
(Group I versus Group III).
Survival free from all-cause mortality and HF-related
hospitalization was 76% in Group I patients versus 64% in
Group II patients and 36% of Group III patients (X2 72.4;
p< 0.0001). Mantel–Cox analysis showed statistically sig-
niﬁcant diﬀerences between Group I and Group II patients
(X2 8.1; p � 0.004), between Group I and Group III patients
(X2 59.2; p< 0.0001), and between Group II and Group III
patients (X2 34.1; p< 0.0001) (Figure 3). /e number needed
to spare one event was 7 (Group I versus Group II) and 3
(Group I versus Group III).
/e impact of Group I strategy on survival was eval-
uated by Cox analysis. Primary end point (all-cause
mortality) results are shown in Table 2. Several univari-
ate predictors of all-cause mortality were identiﬁed.
However, only follow-up BNP >125 pg/ml and decrease≤30%, averaged E/e′, and LVEF remained independently
associated with outcome on multivariate analysis. /e
combined end point of death and HF hospitalization was
associated with a number of variables on univariate
analysis. Multivariate predictors of the combined end
point are shown in Table 3. Particularly, BNP >125 pg/ml
and decrease ≤30%, presence of ≥15 chest B-lines, and
LVEF at follow-up were independently associated with the
outcome.
As far as changes in medication during the observation
period are concerned, the use of loop diuretics decreased
by 11% in Group I and increased by 4.2% in Group II,
beta-blocker use increased by 21.3% in Group I and by
0.9% in Group II, the use of ACE inhibitors or angiotensin
receptor antagonists increased by 1.5% in Group I and
decreased by 10.5% in Group II, and the use of miner-
alocorticoid receptor inhibitors decreased by 8.6% in
Group I and increased by 1.8% in Group II. Eighty-three
patients of Group I, who had been previously treated with
ACE inhibitors or angiotensin receptor antagonists, re-
ceived sacubitril/valsartan that was titrated to the maxi-
mal tolerated dose. At the end of follow-up, 68 patients of
Group I and 53 patients of Group II had a cardioverter
deﬁbrillator implanted, whereas 40 and 44, respectively,
were submitted to cardiac resynchronization therapy.
4. Discussion
/emain ﬁnding of our study is that follow-up care directed
by echo and BNP improved survival in ambulatory patients
with HF and reduced or mildly reduced LVEF with respect
to patients followed by conventional clinical parameters and
those who received no dedicated follow-up. Tissue Doppler
index E/e′was the best predictor of survival in patients of the
echo- and BNP-guided group. In addition, presence of
pulmonary congestion as assessed by the increased number
of B-lines at LUS was another clinically measurable predictor
of outcome.
After hospital discharge, patients with HF remain at high
risk of mortality and rehospitalization, particularly during
the ﬁrst few weeks [17, 18]. In most countries, only a mi-
nority of patients gain access to a dedicated outpatient clinic,
which can provide speciﬁc follow-up visits for cardiovas-
cular care [19].
Cardiology Research and Practice 3
Care management programs for HF have traditionally
focused on patients with chronic HF at high risk of de-
compensation detected during outpatient follow-up. /e
growing pressure from hospital readmissions in HF patients
is shifting the focus of interest from traditionally symptom-
guided care to a more speciﬁc patient-centered follow-up
care based on clinical ﬁndings, NPs, and echo [20, 21].
As it is known, NP-guided therapy has not received an
endorsement as the recommended approach for HF man-
agement by the American and European society guidelines
[22, 23]. In the recent GUIDE-IT study, where HF patients
with LVEF≤ 40% were randomized to either an NT-
proBNP-guided strategy or usual care, no signiﬁcant dif-
ferences have been reported between the NP-guided arm
and the usual care arm in reducing time to ﬁrst hospitali-
zation or cardiovascular mortality. However, a major lim-
itation of GUIDE-IT was that a single target value of NT-
proBNP< 1,000 pg/mL was utilized [24].
Regardless of the etiology, increases in LVFP and pul-
monary congestion are necessary prerequisites to de-
compensation. In addition to echo Doppler variables that
allow estimation of LVFP, that is, E/e′ and EDT, LUSmay be
utilized for the prediction of decompensated HF [25]. /e
ability to distinguish stable from unstable HF patients may
be reﬁned by the concomitant assessment of NP circulating
levels and their variations over time [26].
In the last years, LUS has been proposed for the eval-
uation of pulmonary congestion, through the assessment of
B-lines. Quantiﬁcation of B-lines has been shown to be
useful for the diagnosis, monitoring, and risk stratiﬁcation of
patients with known or suspected acute HF [27] and may
add to the assessment of hemodynamic congestion by echo
Doppler parameters and NPs also in an outpatient setting
[12, 28]. /e echo Doppler estimation of LVFP by E/e′ and
NPs is somewhat correlated with pulmonary tissue water in
large populations, but may provide diﬀerent information in
the single patient [29].
Beyond the prognostic value of reducing NPs to less than
a speciﬁc numeric value, changes in NP concentrations over
Table 1: Demographic, clinical, and echocardiographic baseline characteristics of the study groups.
Variable Group I (n � 224) Group II (n � 293) Group III (n � 277) p value
Age (years) 67± 12 68± 11++ 70± 10‡‡ <0.0001
Follow-up (months) 35 (12–66) 36 (19–65) 39 (20–55) 0.057
Male (%) 78 80 80 0.72
Heart rate (beats/min) 75± 14 76± 15 75± 15 0.22
Ischemic CM (%) 50 59 62‡‡ 0.024
eGFR <60ml/m2 (%) 33 40 36 0.27
DM (%) 30 24 22‡ 0.13
History of hypertension 46 49 45 0.59
Atrial ﬁbrillation (%) 19 16 19 0.54
NYHA class> II (%) 24 27 31 0.18
Systolic BP (mmHg) 123± 18∗∗ 133± 20++ 124± 17‡‡ <0.0001
Diastolic BP (mmHg) 74± 10∗∗ 76± 15++ 73± 9‡‡ <0.0001
LV EDVi (ml/m2) 100± 33∗∗ 86± 33++ 109± 32‡‡ <0.0001
LV ESVi (ml/m2) 68± 29∗∗ 59± 31++ 75± 29‡‡ <0.0001
LVEF (%) 33± 8 34± 9 33± 8‡ 0.070
Mitral regurgitation† (%) 28 29 37 0.039
EDT (msec) 179± 58∗∗ 212± 62 159± 53‡‡ <0.0001
Loop diuretics (%) 82 82 86 0.27
Beta-blockers (%) 69∗ 79++ 66 0.016
ACE inhibitors or angiotensin receptor inhibitors (%) 89 86++ 76‡‡ 0.003
Mineralocorticoid receptor inhibitors (%) 62 58 51 0.29
CRT (%) 9 8 8 0.90
ICD (%) 17 11 12 0.071
CM: cardiomyopathy; eGFR: estimated glomerular ﬁltration rate; DM: diabetes; NYHA: New YorkHeart Association; BP: blood pressure; LV: left ventricular;
EDVi: end-diastolic volume index; ESVi: end-systolic volume index; LVEF: left ventricular ejection fraction; EDT: E-wave deceleration time; CRT: cardiac
resynchronization therapy; ICD: implantable cardioverter deﬁbrillator.∗: p< 0.05,∗∗: p< 0.01 echo- and BNP-guided group versus symptom-guided group;
+: p< 0.05, ++: p< 0.01 symptom-guided group versus no follow-up; ‡: p< 0.05, ‡‡: p< 0.01 echo- and BNP-guided group versus no follow-up.
% p = 0.044
p = 0.020
p = 0.005
50
45
40
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EDT E/e′ B-lines
Figure 2: Frequencies of patients with an E-wave deceleration time
(EDT)< 150ms, a ratio of E/averaged myocardial early velocity
(averaged E/e′)≥ 13, and presence of ≥15 B-lines at lung ultra-
sound. Comparison between baseline (dark gray bar) and follow-up
(light gray bar).
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time may help to better stratify the risk [30]. /is is the
reason why, rather than simply rely on ﬁxed BNP values, we
have used a combination of follow-up BNP <125 pg/ml and
decrease >30% as targets of therapy [31].
Our results support the use of Doppler echocardio-
graphic signs of raised LVFP and LUS with BNP in the
follow-up of HF outpatients with reduced or mildly reduced
EF. /e improvement in clinical outcome of ambulatory
patients with systolic HF who underwent follow-up evalu-
ations that included echocardiography, LUS, and the as-
sessment NPs can be attributed to prevention of clinically
overt pulmonary congestion, refractoriness to loop diuretics,
and a better titration of cardiovascular drugs. Moreover,
repeated echocardiograms during follow-upmay be valuable
for the earlier identiﬁcation of candidates to surgical and
percutaneous valve interventions, cardiac resynchronization
therapy, and cardioverter deﬁbrillator implantation. Finally,
drug treatments with newer pharmacological entities, such
as sacubitril/valsartan, that have been recently introduced in
the clinical scenario, may importantly contribute to improve
patients’ prognosis and decrease the occurrence of wors-
ening HF [32].
Our study has several limitations. Data were collected
retrospectively, and follow-up visits were planned and made
according to diﬀerent protocols. Despite the recent devel-
opment of more sophisticated echocardiographic
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Figure 3: (a) Survival free from all-cause mortality in patients of the echo- and BNP-guided follow-up, in patients of the clinically driven
follow-up, and in those who received no speciﬁc follow-up care (X2 53.5; p< 0.0001). (b) Survival curves for the combined end point of death
or hospitalization for worsening heart failure in echo- and BNP-guided and symptom-guided groups and in patients who received no
speciﬁc follow-up care (X2 72.4; p< 0.0001). When compared to patients of the symptom-guided group and those who did not receive any
organized follow-up care, life was estimated to be prolonged by an average of 2.5 years and 4 years, respectively, by the echo- and BNP-
guided strategy. Similar results were attained with the event-free life gain.
Cardiology Research and Practice 5
techniques, for example, speckle tracking spectral Doppler
[33], echo Doppler markers of raised LVFP are well validated
and universally used.
Due to its simple application, repeatability, and open
access in daily HF management, assessment of markers of
raised LVFP and LUS in association with repeated de-
termination of NP circulating levels appears valuable to guide
therapy of ambulatory HF patients. Nevertheless, further
work is necessary to validate our ﬁndings and this in-
vestigation must be considered only a hypothesis-generating
study whose results need to be conﬁrmed by a prospective
randomized trial. /e E/e′, which is one of the parameters
used to determine diastolic dysfunction as per the most recent
guidelines, should be followed over time in future studies.
Data Availability
/e datasets generated during and/or analysed during the
current study are available from the corresponding author
on reasonable request.
Table 2: Univariate and multivariate predictors of all-cause mortality among 224 patients of the BNP- and echo-guided group.
Variable
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age 1.03 (1.00, 1.05) 0.043
Male 0.98 (0.51, 1.97) 0.98
Heart rate 1.01 (1.00, 1.03) 0.11
Ischemic CM 1.23 (0.88, 1.72) 0.29
Diabetes 1.98 (1.13, 3.45) 0.021
Hypertension 0.97 (0.55, 1.73) 0.93
Atrial ﬁbrillation 1.39 (0.68, 2.85) 0.38
NYHA class 2.38 (1.67, 3.38) <0.0001
Systolic BP 0.97 (0.95, 0.99) 0.0022
Diastolic BP 0.96 (0.93, 0.99) 0.0032
eGFR 0.98 (0.97, 0.99) 0.0040
BNP 1.00 (1.00, 1.00) <0.0001
BNP >125 pg/ml or decrease ≤30% 5.74 (2.97, 11.07) <0.0001 1.55 (1.35, 1.77) 0.0038
LVEF 0.89 (0.85, 0.92) <0.0001 0.94 (0.89, 1.00) 0.051
Mitral regurgitation 3.58 (3.00, 6.38) <0.0001
EDT 0.99 (0.98, 0.99) <0.0001
E/e′ averaged 1.06 (1.04, 1.08) <0.0001 1.05 (1.02, 1.08) 0.0054
B-lines≥ 15 7.32 (4.13, 12.96) <0.0001
HR: hazard ratio. For other abbreviations, see Table 1.
Table 3: Univariate and multivariate predictors of the combined end point among 224 patients of the BNP- and echo-guided group.
Variable
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Age 1.03 (1.00, 1.05) 0.071
Male 0.56 (0.24, 1.37) 0.56
Heart rate 1.02 (1.01, 1.04) 0.026
Ischemic CM 1.14 (0.67, 1.94) 0.64
Diabetes 3.14 (1.44, 6.80) 0.0057
Hypertension 1.41 (0.62, 3.23) 0.42
Atrial ﬁbrillation 1.62 (0.8, 4.55) 0.38
NYHA class 2.29 (1.37, 3.84) 0.0016
Systolic BP 0.98 (0.96, 1.00) 0.14
Diastolic BP 0.95 (0.91, 0.99) 0.0079
eGFR 0.98 (0.96, 0.99) 0.0073
BNP 1.00 (1.00, 1.00) 0.0033
BNP >125 pg/ml or decrease ≤30% 8.52 (2.89, 25.16) <0.0001 2.48 (1.14, 5.42) 0.023
LVEF 0.88 (0.84, 0.94) <0.0001 0.95 (0.91, 1.00) 0.052
Mitral regurgitation 3.58 (3.00, 6.38) <0.0001
EDT 0.98 (0.97, 0.99) <0.0001
E/e′ averaged 1.06 (1.04, 1.09) <0.0001
B-lines≥ 15 5.64 (2.47, 12.83) <0.0001 2.62 (1.26, 5.42) 0.0099
For abbreviations, see Table 2.
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